Brainstorm Cell Therapeutics Inc. (BCLI) Balance Sheet
BCLI balance sheet, 2025
December 31, 2025 · U.S. dollars$715,000 assets = $11.0M liabilities + −$10.3M equity
Liabilities exceed assets: shareholders’ equity is negative (−$10.3M).
Both columns are drawn to the same scale: what BCLI owns equals what it owes plus shareholders’ equity. Hover a block for its value.
BCLI financial health
Descriptive bands, not a rating. Fiscal 2025.
BCLI balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $10.8M2016 | $715,0002025 | −26.0%/yr | |
| Total liabilities | $864,0002016 | $11.0M2025 | +32.7%/yr | |
| Shareholders’ equity | $9.9M2016 | −$10.3M2025 | — | |
| Cash & short-term investments | $10.0M2016 | $29,0002025 | −47.7%/yr | |
| Total debt | $2.4M2019 | $208,0002025 | −33.3%/yr | |
| Net cash (debt) | −$1.8M2019 | −$179,0002025 | +$1.6M | |
| Working capital | $9.6M2016 | −$10.7M2025 | −$20.3M | |
| Book value per share | $15.712020 | −$1.112025 | — | |
| Current ratio | 12.092016 | 0.032025 | −12.06 | |
| Debt / equity | 0.202020 | 0.262021 | +0.06 | |
| Shares outstanding | 2.3M2020 | 9.3M2025 | +32.6%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
BCLI assets
BCLI liabilities and equity
BCLI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
BCLI balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $29,000 | $187,000 | $1.3M | $3.0M | $22.1M | $41.9M | $569,000 | $7.1M | $7.8M | $10.0M |
| Cash & equivalents | $29,000 | $187,000 | $1.3M | $772,000 | $18.9M | $37.8M | $536,000 | $942,000 | $2.5M | $547,000 |
| Short-term investments | — | — | $0 | $2.2M | $3.2M | $4.1M | $33,000 | $6.1M | $5.3M | $9.4M |
| Receivables | $86,000 | $63,000 | $51,000 | $91,000 | $86,000 | $304,000 | $2.4M | $2.0M | $672,000 | $306,000 |
| Inventory | $0 | $0 | −$51,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $192,000 | $135,000 | $599,000 | $32,000 | $1.1M | $1.0M | $432,000 | $1.2M | $1.2M | $148,000 |
| Total current assets | $307,000 | $385,000 | $1.9M | $3.1M | $23.3M | $43.2M | $3.4M | $10.3M | $9.6M | $10.4M |
| Property, plant & equipment (net) | $443,000 | $1.2M | $2.1M | $5.3M | $6.0M | $8.0M | $3.1M | $651,000 | $392,000 | $297,000 |
| Goodwill & intangible assets | $0 | $0 | $3,000 | $9 | $17,000 | $27,000 | $13,000 | $16 | $13 | $16 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $206,000 | $204,000 | $22,991 | $27,000 | $26,000 | $32,000 | $306,984 | $1.4M | $24,984 |
| Total assets | $715,000 | $1.8M | $4.2M | $8.5M | $29.3M | $51.3M | $6.5M | $11.2M | $11.4M | $10.8M |
| Liabilities | ||||||||||
| Accounts payable | $7.1M | $6.1M | $5.0M | $6.2M | $3.7M | $5.4M | $14.7M | $4.5M | $2.1M | $712,000 |
| Short-term debt | $208,000 | $549,000 | $603,000 | $1.4M | $1.5M | $2.7M | $1.3M | — | — | — |
| Deferred revenue | — | — | −$603,000 | — | — | — | — | — | $2.6M | — |
| Total current liabilities | $11.0M | $9.0M | $7.8M | $8.8M | $6.3M | $11.2M | $17.7M | $6.2M | $5.5M | $864,000 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $208,000 | $720,000 | $1.3M | $4.1M | $5.1M | $7.2M | $2.4M | — | — | — |
| Other long-term liabilities | $208,000 | $618,000 | $1.3M | $2.7M | $3.6M | $4.6M | $1.1M | $5.2M | $4.7M | $712,000 |
| Total liabilities | $11.0M | $9.6M | $9.1M | $11.5M | $9.9M | $15.8M | $18.8M | $6.2M | $5.5M | $864,000 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $16,000 | $14,000 | $13,000 | $12,000 | $12,000 | $12,000 | $11,000 | $11,000 | $11,000 | $11,000 |
| Retained earnings (deficit) | −$236.9M | −$226.6M | −$215.0M | −$197.8M | −$173.5M | −$149.1M | −$117.3M | −$94.0M | −$80.1M | −$75.1M |
| Treasury stock | — | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | — | — | $0 | $0 | $0 | $0 | −$1.7M | $4.4M | −$1.5M | −$1.4M |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | −$10.3M | −$7.8M | −$4.9M | −$3.0M | $19.3M | $35.5M | −$12.2M | $5.0M | $5.9M | $9.9M |
| Key figures | ||||||||||
| Total debt | $208,000 | $720,000 | $1.3M | $4.1M | $5.1M | $7.2M | $2.4M | — | — | — |
| Net cash (debt) | −$179,000 | −$533,000 | $25,000 | −$1.1M | $17.0M | $34.7M | −$1.8M | — | — | — |
| Working capital | −$10.7M | −$8.6M | −$5.9M | −$5.7M | $17.0M | $32.0M | −$14.3M | $4.1M | $4.1M | $9.6M |
| Tangible book value | −$10.3M | −$7.8M | −$4.9M | −$3.0M | $19.3M | $35.4M | −$12.2M | $5.0M | $5.9M | $9.9M |
| Book value per share | −$1.11 | −$1.46 | −$1.27 | −$1.23 | $7.98 | $15.71 | — | — | — | — |
| Shares outstanding | 9.3M | 5.3M | 3.8M | 2.4M | 2.4M | 2.3M | — | — | — | — |
| Current ratio | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 |
| Quick ratio | 0.01 | 0.03 | 0.17 | 0.35 | 3.51 | 3.76 | 0.17 | 1.46 | 1.52 | 11.92 |
| Debt / equity | — | — | — | — | 0.26 | 0.20 | — | — | — | — |
| Equity / assets | −1,439.4% | −423.8% | −115.4% | −35.7% | 66.1% | 69.2% | −187.1% | 44.7% | 51.5% | 92.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $22,000 | $15,000 | $29,000 | $5,000 | $824,000 | $1.6M | $187,000 | $168,000 | $3.5M | $779,000 | $1.3M | $1.4M |
| Cash & equivalents | $22,000 | $15,000 | $29,000 | $5,000 | $824,000 | $1.6M | $187,000 | $168,000 | $3.5M | $779,000 | $1.3M | $1.2M |
| Short-term investments | — | — | — | — | — | — | — | — | — | — | $0 | $196,000 |
| Receivables | $162,000 | $122,000 | $86,000 | $80,000 | $106,000 | $67,000 | $63,000 | $40,000 | $33,000 | $26,000 | $0 | $66,000 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $132,000 | $47,000 | $192,000 | $423,000 | $585,000 | $621,000 | $135,000 | $156,000 | $314,000 | $454,000 | $599,000 | $55,000 |
| Total current assets | $316,000 | $184,000 | $307,000 | $508,000 | $1.5M | $2.3M | $385,000 | $364,000 | $3.8M | $1.3M | $1.9M | $1.5M |
| Property, plant & equipment (net) | $258,000 | $355,000 | $443,000 | $617,000 | $826,000 | $1.0M | $1.2M | $1.5M | $1.7M | $1.9M | $2.1M | $4.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3,000 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $32,000 | $0 | $0 | $225,000 | $204,000 | $206,000 | $203,000 | $199,000 | $199,000 | $207,000 | $21,000 |
| Total assets | $472,000 | $571,000 | $715,000 | $872,000 | $2.6M | $3.6M | $1.8M | $2.0M | $5.7M | $3.3M | $4.2M | $5.7M |
| Liabilities | ||||||||||||
| Accounts payable | $7.5M | $7.3M | $7.1M | $6.4M | $6.0M | $6.8M | $6.1M | $4.6M | $5.3M | $4.7M | $5.0M | $3.9M |
| Short-term debt | $1.4M | $1.5M | $1.4M | $377,000 | $482,000 | $1.6M | $549,000 | $570,000 | $566,000 | $588,000 | — | $1.3M |
| Total current liabilities | $12.4M | $11.8M | $11.0M | $9.0M | $8.5M | $10.9M | $9.0M | $7.1M | $7.7M | $6.8M | $7.8M | $6.3M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $113,000 | $159,000 | $208,000 | $326,000 | $476,000 | $570,000 | $720,000 | $841,000 | $962,000 | $1.1M | $1.3M | $2.9M |
| Other long-term liabilities | $0 | $0 | $208,000 | $326,000 | $95,000 | $127,000 | $618,000 | $1.0M | $1.5M | $2.1M | $1.3M | $1.9M |
| Total liabilities | $12.4M | $11.8M | $11.0M | $50,000 | $8.6M | $11.0M | $9.6M | $8.1M | $9.2M | $8.9M | $9.1M | $8.3M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $16,000 | $16,000 | $16,000 | $16,000 | $16,000 | $15,000 | $14,000 | $14,000 | $14,000 | $13,000 | — | $12,000 |
| Retained earnings (deficit) | −$242.9M | −$239.1M | −$236.9M | −$234.5M | −$232.4M | −$229.5M | −$226.6M | −$223.7M | −$221.0M | −$218.4M | −$215.0M | −$209.4M |
| Accumulated other comprehensive income | — | — | — | — | — | — | — | $0 | — | $0 | — | $0 |
| Total shareholders' equity | −$11.6M | −$11.0M | −$10.3M | $822,000 | −$6.1M | −$7.5M | −$7.8M | −$6.1M | −$3.5M | −$5.5M | −$4.9M | −$2.6M |
| Key figures | ||||||||||||
| Total debt | $1.4M | $1.5M | $208,000 | $326,000 | $577,000 | $1.8M | $720,000 | $841,000 | $962,000 | $1.1M | — | $2.9M |
| Net cash (debt) | −$1.4M | −$1.5M | −$179,000 | −$321,000 | $247,000 | −$126,000 | −$533,000 | −$673,000 | $2.5M | −$342,000 | — | −$1.5M |
| Working capital | −$12.1M | −$11.6M | −$10.7M | −$8.5M | −$7.0M | −$8.6M | −$8.6M | −$6.7M | −$3.9M | −$5.6M | −$5.9M | −$4.8M |
| Tangible book value | −$11.6M | −$11.0M | −$10.3M | $822,000 | −$6.1M | −$7.5M | −$7.8M | −$6.1M | −$3.5M | −$5.6M | −$4.9M | −$2.6M |
| Book value per share | −$1.05 | −$1.00 | −$1.11 | $0.07 | −$0.70 | −$1.18 | −$1.36 | −$1.14 | −$0.74 | −$1.29 | −$1.20 | −$0.88 |
| Shares outstanding | 11.0M | 11.0M | 9.3M | 11.0M | 8.6M | 6.3M | 5.7M | 5.3M | 4.7M | 4.3M | 4.0M | 3.0M |
| Current ratio | 0.03 | 0.02 | 0.03 | 0.06 | 0.18 | 0.21 | 0.04 | 0.05 | 0.50 | 0.18 | 0.24 | 0.24 |
| Quick ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.11 | 0.16 | 0.03 | 0.03 | 0.46 | 0.12 | 0.17 | 0.23 |
| Debt / equity | — | — | — | 0.40 | — | — | — | — | — | — | — | — |
| Equity / assets | −2,457.0% | −1,928.0% | −1,439.4% | 94.3% | −236.0% | −208.8% | −423.8% | −299.1% | −62.1% | −165.8% | −115.4% | −45.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
BCLI financial position
At the end of fiscal 2025 (December 31, 2025), Brainstorm Cell Therapeutics had total assets of $0.7 million (down 61.0% from a year earlier), total liabilities of $11.0 million and shareholders' equity of -$10.3 million. It held $0.0 million in cash and short-term investments against $0.2 million of debt, net debt of $0.2 million. Its current ratio was 0.03. In the latest quarter (ended June 30, 2026) total assets were $0.5 million and equity -$11.6 million.
Related: BCLI income statement, BCLI cash flow statement, BCLI key metrics. See the BCLI stock overview for the latest quote and news.
BCLI balance sheet FAQ
What are Brainstorm Cell Therapeutics's total assets?
Brainstorm Cell Therapeutics reported total assets of $0.7 million at the end of fiscal 2025 (December 31, 2025), compared with $1.8 million a year earlier.
How much debt does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics had $0.2 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics held $0.0 million in cash and short-term investments at the end of fiscal 2025; with $0.2 million of debt that is net debt of $0.2 million.
What is Brainstorm Cell Therapeutics's book value?
Brainstorm Cell Therapeutics's shareholders' equity (book value) was -$10.3 million at the end of fiscal 2025, or −$1.11 per share.
What is Brainstorm Cell Therapeutics's current ratio?
Brainstorm Cell Therapeutics had current assets of $0.3 million and current liabilities of $11.0 million, a current ratio of 0.03 (current liabilities exceed current assets).